（文章来源：证券日报） 证券日报网讯 12月19日晚间，美迪凯发布公告称，公司2025年第一次临时股东会审议通过《关于公司 符合向特定对象发行A股股票条件的议案》《关于公司2025年度向特定对象发行A股股票方案的议案》 《关于公司〈2025年度向特定对象发行A股股票预案〉的议案》等多项议案。 ...

证券代码：688079 证券简称：美迪凯 公告编号：2025-054 杭州美迪凯光电科技股份有限公司 2025年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （四） 表决方式是否符合《公司法》及公司章程的规定，股东会主持情况等。 本次股东会由公司董事会召集，董事长葛文志先生主持，采用现场投票与网 络投票相结合的表决方式。本次股东会的召集、召开及表决程序符合《公司法》 和公司章程的相关规定。 （五） 公司董事和董事会秘书的列席情况 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 12 月 19 日 （二） 股东会召开的地点：浙江省嘉兴市海宁市长安镇新潮路 15 号浙江美迪凯 光学半导体有限公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 97 | | --- | --- | | 普通股股东人数 | 97 | | 2、出席会议的股东所持有的 ...

国浩律师(上海) 事务所 关 于 杭州美迪凯光电科技股份有限公司 2025 年第一次临时股东会 为出具本法律意见书,本所律师出席了本次股东会,审查了公司提供的有关 本次大会各项议程及相关文件，听取了公司董事会就有关事项所作的说明。 N 法律意见书 浩律師事務所 RANDAII I AW FIRM 上海市静安区山西北路 99 号苏河湾中心 MT25-28 楼 邮编：200085 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai 200085, China 电话/Tel: +86 21 5234 1668 传真/Fax: +86 21 5234 1670 网址/Website: http://www.grandall.com.cn 二零二五年十二月 l 国浩律师（上海）事务所 关于杭州美迪凯光电科技股份有限公司 2025 年第一次临时股东会之法律意见书 致:杭州美迪凯光电科技股份有限公司 杭州美迪凯光电科技股份有限公司(以下简称"公司")2025年第一次临时 股东会于 2025 年 12 月 19 日召开 。国浩律师 (上 ...

Policy - The Central Economic Work Conference emphasized the implementation of a new round of high-quality development actions for key industrial chains, focusing on innovation-driven growth and the establishment of international technology innovation centers in major regions [1] - Xiamen's 14th Five-Year Plan suggests strengthening efficient supply of computing power, algorithms, and data, promoting digital transformation across the city, and enhancing the integration of the digital economy with the real economy [1] Investment Activities - Shanghai Future Industry Fund plans to invest in five sub-funds, including Shanghai Lianxue Venture Capital and Shanghai Innovation Workshop Venture Capital [4] - Zhongqi Technology completed a financing round of over 500 million RMB, with participation from various institutional investors [7] - Star Source Intelligent Robot completed a financing round exceeding 100 million RMB, focusing on multi-modal spatial intelligence [9] - Ling Sheng Technology completed approximately 100 million RMB in Pre-A financing, aimed at accelerating the development of brain-like technology [10] - Zhuoyue Intelligent completed 200 million RMB in C round financing, focusing on intelligent drone systems [11] Market Developments - Moore Threads is set to unveil a new generation GPU architecture at the upcoming MUSA Developer Conference [13][14] - China Shipbuilding Special Gas announced an investment of approximately 870 million RMB for a project to produce high-purity hydrogen sulfide and other electronic gases [14] - Xingfu Electronics plans to invest 480 million RMB in a project for electronic-grade phosphoric acid, driven by increasing demand in semiconductor manufacturing [14] - Tongyizhong intends to invest about 198 million RMB in a project for ultra-high molecular weight polyethylene fiber, expanding its applications in various fields [15]

证券代码：688079 证券简称：美迪凯 杭州美迪凯光电科技股份有限公司 2025 年第一次临时股东会会议资料 2025 年 12 月 杭州美迪凯光电科技股份有限公司 2025 年第一次临时股东会会议资料 杭州美迪凯光电科技股份有限公司 2025 年第一次临时股东会资料目录 | 2025 年第一次临时股东会会议须知 | | 3 | | --- | --- | --- | | 2025 年第一次临时股东会会议议程 | | 5 | | 关于公司符合向特定对象发行 A 股股票条件的议案 | | 7 | | 关于公司 2025 年度向特定对象发行 A 股股票方案的议案 | | 8 | | 关于公司《2025 年度向特定对象发行 | A 股股票预案》的议案 | 12 | | 关于公司《2025 年度向特定对象发行 A 股股票方案论证分析报告》的议案 | | 13 | | 关于公司《2025 年度向特定对象发行 A 股股票募集资金投资项目可行性分析报告》 | | | | 的议案 | | 14 | | 关于公司《前次募集资金使用情况报告》的议案 | | 15 | | 关于公司向特定对象发行 A 股股票摊薄即期回报、填补措施 ...

Core Viewpoint - Meidike's subsidiary, Zhejiang Meidike Optical Semiconductor Co., Ltd., is raising capital through a strategic investment from Zhejiang Fuzhe Shaoxin Integrated Circuit Industry Fund, with a pre-investment valuation of 2.18 billion yuan, indicating a 21% increase from the previous year's valuation [1][4]. Group 1: Investment and Financial Details - The strategic investor, Fuzhe Shaoxin, will invest 200 million yuan, acquiring an 8.40% stake in the optical semiconductor company, which remains a subsidiary of Meidike [1][4]. - The optical semiconductor company has experienced cumulative losses of 149 million yuan from 2023 to the first nine months of 2025 [1][6]. - Meidike's total assets reached 3.264 billion yuan with a debt ratio of 58.88% as of September 2025, reflecting increased financial pressure [7]. Group 2: Business Performance and Challenges - The optical semiconductor company reported revenues of 205 million yuan, 313 million yuan, and 264 million yuan for the years 2023 to the first nine months of 2025, with net losses of 40.66 million yuan, 42.48 million yuan, and 65.77 million yuan respectively [6]. - Meidike's revenue increased by 32.04% to 451 million yuan in the first three quarters of 2025, but net losses also grew due to rising costs in depreciation, labor, and financial expenses [7]. - The company is in a capacity ramp-up phase, facing challenges from long certification cycles for new technologies and increased operational costs [6][7]. Group 3: Future Plans and Strategic Moves - Meidike plans to raise up to 700 million yuan through a private placement to enhance its optical and semiconductor product matrix and capacity layout [8]. - The company aims to improve its financial resilience and operational capabilities through this capital increase and strategic partnerships [8].

Group 1 - Dingyang Technology has launched the SPB3000X series source load simulator, which includes three models: SPB3100X, SPB3200X, and SPB3300X, featuring high precision, low ripple noise, and fast transient response [1] - Ningbo Huaxiang plans to acquire 40% of Fengmei Power's equity from SAIC Volkswagen, with the total acquisition involving 100% equity [2] - ST Jiaotou will implement a capital reserve conversion to increase share capital, with a total of 267 million shares to be converted [3] Group 2 - Century Huatong's subsidiary Guosheng Capital holds 19.5887 million shares of Moer Thread, accounting for 4.8968% of the total share capital before the IPO [4] - Meidike intends to introduce strategic investors to its subsidiary, with an investment of 200 million yuan at a pre-investment valuation of 2.18 billion yuan [5] - Baiyun Airport reported a 12.58% year-on-year increase in passenger throughput in November, totaling 7.3228 million passengers [6] Group 3 - Shengda Resources' subsidiary Honglin Mining has received approval for a three-month extension for trial production [7] - ST Yigou's subsidiary Suning International is expected to increase net profit by approximately 992 million yuan from the sale of eight subsidiaries [8][9] - Huayi Brothers reported overdue debts totaling 52.5 million yuan, exceeding 10% of its audited net assets for 2024 [10] Group 4 - Wanshun New Materials plans to acquire 100% of Eurofoil Luxembourg for 12.3889 million euros, enhancing its aluminum foil production capabilities [11] - Wuhan Tianyuan's subsidiary plans to invest approximately 600 million yuan in two energy storage projects [12] - Maike Biological's subsidiary has received a product registration certificate for a new automatic cell morphology analyzer [13] Group 5 - CATL intends to register for the issuance of bonds not exceeding 10 billion yuan, primarily for project construction and working capital [14] - Yuntianhua plans to acquire 100% of Tianyao Chemical for 36.8858 million yuan, enhancing its fine phosphorus chemical product line [15] - Fucheng Technology's controlling shareholder has reduced its stake by 1.0429 million shares [16] Group 6 - Zhili Fang plans to reduce its stake by up to 1.2% of the company's total shares [17][18] - Qianzhao Optoelectronics' chairman intends to reduce his stake by up to 0.02% [19] - Sanmu Group's subsidiary plans to sell 75 office properties for 24.1068 million yuan [20] Group 7 - Zhuangyuan Pasture's director plans to reduce his stake by up to 3% of the company's total shares [21] - Chongqing Pharmaceutical's subsidiary has signed a licensing agreement with Pfizer, potentially earning up to 50 million USD in milestone payments [22] - Yongqing Environmental Protection's shareholder plans to reduce its stake by up to 1% [23] Group 8 - Lens Technology plans to acquire 100% of PMG International Co., Ltd., enhancing its capabilities in server cabinet business [24] - Xinbang Pharmaceutical is facing prosecution for alleged unit bribery, but its control remains unchanged [25] - Meian Health's shareholders plan to reduce their stake by up to 3% of the company's total shares [26] Group 9 - Central Plaza's subsidiary has decided to suspend operations due to ongoing operational difficulties [27] - Dawn Co. plans to acquire 80% of Ningbo Aisikai for 516 million yuan, including the transfer of related patents and technologies [28] - Kweichow Moutai will distribute over 30 billion yuan in cash dividends based on its 2025 mid-term profit distribution plan [29] Group 10 - Baiyun Airport has received approval from the CSRC for a stock issuance to specific targets [29] - Zai Sheng Technology reported that revenue from aerospace-related products will account for less than 0.5% of its total revenue in 2024 [30]

美联储降息25个基点。 财政部拟发行7500亿元到期续作特别国债。 11月CPI同比上涨0.7%。 沐曦股份披露首次公开发行股票并在科创板上市发行结果，网上20349股遭弃购。 今日关注 重要的消息有哪些 1．国际货币基金组织（IMF）12月10日在京表示，尽管面临多重冲击，中国经济仍展现出显著韧性。IMF预 计2025年中国经济增速将达5%，较今年10月发布的《世界经济展望报告》上调0.2个百分点。 2．财政部将于12月12日开展2025年到期续作特别国债发行。财政部有关负责人就此接受采访表示，2025年到 期续作的7500亿元特别国债将在全国银行间债券市场面向有关银行定向发行，期限品种包括10年期4000亿元、 15年期3500亿元。发行过程不涉及社会投资者，个人投资者不能购买。2025年到期续作特别国债是原特别国债 的等额滚动发行，仍与原有资产负债相对应，不增加财政赤字。 3．12月10日，国家统计局公布数据显示，11月份居民消费价格指数（CPI）同比上涨0.7%，涨幅扩大；扣除 食品和能源价格的核心CPI同比上涨1.2%，涨幅连续3个月保持在1%以上。同期，工业生产者出厂价格指数 （PPI）环比上涨0 ...

Core Viewpoint - The company Medike (688079) has approved a capital increase for its subsidiary, Zhejiang Medike Optical Semiconductor Co., Ltd., by introducing a strategic investor, Zhejiang Fuzhe Shaoxin Integrated Circuit Industry Fund Partnership (Limited Partnership), with an investment of 200 million yuan at a pre-investment valuation of 2.18 billion yuan [1] Group 1: Capital Increase Details - The strategic investor will hold an 8.40% stake in Medike Optical Semiconductor after the capital increase [1] - The funds from this capital increase will primarily be used for the main business of Medike Optical Semiconductor and other purposes agreed upon by the investor [1] - The capital raised cannot be transferred to Medike or its affiliates for any purpose [1] Group 2: Financial Performance - In 2024, Medike Optical Semiconductor is projected to have a revenue of 313 million yuan and a net loss of 42.47 million yuan [2] - For the first three quarters of 2025, the company reported a revenue of 264 million yuan and a net loss of 65.77 million yuan [2] Group 3: Strategic Implications - The capital increase is expected to enhance the financial strength of Medike Optical Semiconductor, meeting the capital needs for its business development and creating synergistic effects [2] - The capital increase agreement includes provisions for potential share buybacks, allowing Medike to repurchase shares from the investor within four years under certain conditions [2] - Medike remains the controlling shareholder of Medike Optical Semiconductor post-capital increase, and the subsidiary will continue to be included in Medike's consolidated financial statements [3] Group 4: Business Strategy - Medike focuses on product differentiation and is actively improving its business and product structure, investing in semiconductor optoelectronics, micro-nano circuits (mainly MEMS), semiconductor packaging and testing, precision optics, micro-nano optics, and smart terminal manufacturing [3] - The company is increasing the proportion of its products in semiconductor optoelectronics, micro-nano circuits, and semiconductor packaging and testing, optimizing its customer structure and enhancing the semiconductor device industry chain [3]

Core Viewpoint - The company Medike (688079) has approved a capital increase for its subsidiary, Zhejiang Medike Optical Semiconductor Co., Ltd., by introducing a strategic investor, which is expected to enhance its financial strength and core competitiveness [1][2] Group 1: Capital Increase Details - The strategic investor, Zhejiang Fuzhe Shaoxin Integrated Circuit Industry Fund Partnership (Limited Partnership), will invest 200 million yuan at a pre-investment valuation of 2.18 billion yuan, acquiring an 8.40% stake in the subsidiary [1] - After the capital increase, Medike's ownership in the optical semiconductor company will decrease to 82.44%, while the stake of the Service Trade Innovation Development Guidance Fund (Limited Partnership) will drop to 9.16% [1] Group 2: Financial Performance - The projected revenue for Medike Optical Semiconductor Co., Ltd. in 2024 is 313 million yuan, with a net loss of 42.47 million yuan; for the first three quarters of 2025, the revenue is expected to be 264 million yuan, with a net loss of 65.77 million yuan [1] Group 3: Strategic Implications - The capital increase is aimed at meeting the capital needs for the main business operations of Medike Optical Semiconductor and is expected to create synergistic effects by pooling various advantageous resources [2] - The agreement includes provisions for potential share buybacks, allowing Medike to repurchase shares from the investor and existing shareholders within four years under certain conditions [2]